

wherein, R^1 represents one or more functional groups on the benzene ring selected from the group consisting of a hydrogen atom, a halogen atom, a lower alkyl group, and a lower alkoxy group; R^2 represents a hydrogen atom, an alkyl group, or an acyl group; R^3 represents one or more functional groups on the ring containing the nitrogen atom and A; A represents CH_2 , or CH which forms a double bond with an adjacent carbon atom; L represents a $\text{C}_4\text{-C}_8$ alkylene group or an ethyleneoxy linking group represented by $(\text{CH}_2\text{CH}_2\text{O})_n\text{CH}_2\text{CH}_2$ wherein n represents 1 or 2; X represents O, S or methylene group; and m represents 0 or 1.

A2

4. (Amended) The compound or a salt thereof according to claim 1, wherein each of R^1 and R^2 represents a hydrogen atom.

5. (Amended) The compound or a salt thereof according to claim 1, wherein L is a $\text{C}_4\text{-C}_8$ alkylene group.


6. (Amended) The compound or a salt thereof according to claim 1, wherein L is a C_5 or C_6 alkylene group.

A3

10. (Amended) The compound or a salt thereof according to claim 7, wherein R^{13} is a functional group selected from the group consisting of a hydrogen atom, an alkyl group, a hydroxyalkyl group, an aryl group, a hydroxy group, and a cyano group.

11. (Amended) The compound or a salt thereof according to claim 7, wherein L^1 is a C_5 or C_6 alkylene group.

12. (Amended) A pharmaceutical composition comprising a compound represented by the following formula (I)



wherein, R¹ represents one or more functional groups on the benzene ring selected from the group consisting of a hydrogen atom, a halogen atom, a lower alkyl group, and a lower alkoxy group; R² represents a hydrogen atom, an alkyl group, or an acyl group; R³ represents one or more functional groups on the ring containing the nitrogen atom and A; A represents CH₂, or CH which forms a double bond with an adjacent carbon atom; L represents a C₄-C₈ alkylene group or an ethyleneoxy linking group represented by (CH₂CH₂O)_nCH₂CH₂ wherein n represents 1 or 2; X represents O, S or methylene group; and m represents 0 or 1, or a physiologically acceptable salt thereof as an active ingredient, and a pharmaceutical additive.

14. (Amended) A method for the prevention and/or treatment of hyperlipidemia which comprises administering an effective amount of a composition according to claim 12 or 21 to a mammal.

15. (Amended) A method for preventing and/or treating arteriosclerosis which comprises administering an effective amount of a composition according to claim 12 or 21 to a mammal.

A4
cont.
16. (Amended) A method for suppressing foaming of a macrophage which comprises administering an effective amount of a composition according to claim 12 or 21 to a mammal.


17. (Amended) A method for retracting arterial sclerosis lesions which comprises administering an effective amount of a composition according to claim 12 or 21 to a mammal.

18. (Amended) A method for inhibiting formation of arterial sclerosis lesions which comprises administering an effective amount of a composition according to claim 12 or 21 to a mammal.

A5
20. (Amended) A method for preventing and/or treating of arteriosclerosis, which comprises administering an effective amount of a composition according to claim 12 or 21 to a human.

✓
Please add the following new claim:

A6
21. A pharmaceutical composition comprising a compound represented by the following formula (II)



wherein, R¹¹ represents one or more functional groups on the benzene ring selected from the group consisting of a hydrogen atom, a halogen atom, a lower alkyl group, and a lower alkoxy group; R¹² represents a hydrogen atom, an alkyl group, or an acyl group; R¹³ represents one or more functional groups on the piperidine ring selected from the group consisting of hydrogen atom, an alkyl group, an aryl group, a hydroxyl group, an alkoxy group, an amino group, an acyl

Response to Response/Election Requirement
U.S. APPLN. NO. 10/019,249

group, a cyano group, a carbamoyl group and an alkoxycarbonyl group; L^1 represents a C_4-C_8

alkylene group; and X represents O, S, or methylene group, or a physiologically acceptable salt

thereof as an active ingredient, and a pharmaceutical additive.

Ab
con

A large, stylized handwritten signature in black ink, appearing to be 'J. H. C.', is written over the signature line.